Could a Type 2 Diabetes Drug Tackle Kidney Stones?
-
Patients with type 2 diabetes who received empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, were almost 40% less likely to have a kidney stone than patients who received placebo during a median 1.5 years of treatment. These findings are from an analysis of pooled data from phase 1-4 clinical trials of empagliflozin for blood glucose control in 15,081 patients with type 2 diabetes.
-
@rajkamal Dedicated randomized prospective clinical trials are needed to confirm these initial observations in patients both with and without type 2 diabetes